President Donald Trump’s administration is preparing a new probe into U.S. trading partners over drug pricing, Aime Williams and George Parker of The Financial Times reports. The investigations will consider if any U.S. trading partners are underpaying for drugs, three people familiar with the matter told the Times. Trump has repeatedly commented that other countries pay less than the U.S. for the same medicines and plans to take action against nations that refuse to “equalize” prices. Publicly traded drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), Novo Nordisk (NVO), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Companies involved the sale of pharmaceuticals include CVS Health (CVS), Cigna (CI), UnitedHealth (UNH), Cardinal Health (CAH), McKesson (MCK) and Cencora (COR).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Bicara sinks after J&J reports head and neck cancer data
- Activist Jana Partners Takes Stake in Cooper Companies, Presses for Strategic Review
- Johnson & Johnson announces new results from Phase 1b/2 OrigAMI-4 study
- Kenvue Stock (KVUE) Plunges on Legal Woes Related to Talc Products
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!